Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 103
Filter
1.
An. bras. dermatol ; 90(6): 837-840, Nov.-Dec. 2015. tab
Article in English | LILACS | ID: lil-769525

ABSTRACT

Abstract: BACKGROUND: Patients with systemic lupus erythematosus seem to belong to different serological and clinical subgroups of the disease. Genetic background can cause the appearance of these subgroups. OBJECTIVE: To determine whether Brazilian patients who have systemic lupus erythematosus and Raynaud's phenomenon differ from those who do not. METHODS: Retrospective analysis of 373 medical records of systemic lupus erythematosus patients studied for demographic, clinical and serological data. A comparative analysis was performed of individuals with and without RP. RESULTS: There was a positive association between Raynaud's phenomenon and age at diagnosis (p=0.02), presence of anti-Sm (p=0.01) antibodies and anti-RNP (p<0.0001). Furthermore, a negative association was found between Raynaud's phenomenon and hemolysis (p=0.01), serositis (p=0.01), glomerulonephritis (p=0.0004) and IgM aCL (p=0.004) antibodies. CONCLUSION: Raynaud's phenomenon patients appear to belong to a systemic lupus erythematosus subset with a spectrum of clinical manifestations located in a more benign pole of the disease.


Subject(s)
Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Young Adult , Lupus Erythematosus, Systemic/physiopathology , Raynaud Disease/physiopathology , Antibodies, Antinuclear/analysis , Brazil , Lupus Erythematosus, Systemic/immunology , Lupus Erythematosus, Systemic/pathology , Medical Records , Retrospective Studies , Raynaud Disease/immunology , Raynaud Disease/pathology , Statistics, Nonparametric
3.
J. bras. pneumol ; 39(6): 728-741, Nov-Dec/2013. graf
Article in English | LILACS | ID: lil-697773

ABSTRACT

The initial evaluation of patients with interstitial lung disease (ILD) primarily involves a comprehensive, active search for the cause. Autoantibody assays, which can suggest the presence of a rheumatic disease, are routinely performed at various referral centers. When interstitial lung involvement is the condition that allows the definitive diagnosis of connective tissue disease and the classical criteria are met, there is little debate. However, there is still debate regarding the significance, relevance, specificity, and pathophysiological role of autoimmunity in patients with predominant pulmonary involvement and only mild symptoms or formes frustes of connective tissue disease. The purpose of this article was to review the current knowledge of autoantibody positivity and to discuss its possible interpretations in patients with ILD and without clear etiologic associations, as well as to enhance the understanding of the natural history of an allegedly new disease and to describe the possible prognostic implications. We also discuss the proposition of a new term to be used in the classification of ILDs: lung-dominant connective tissue disease.


A avaliação inicial de pacientes com doença pulmonar intersticial (DPI) envolve primordialmente a busca ativa e detalhada por uma etiologia. A pesquisa rotineira de autoanticorpos é comum em diferentes centros e permite sugerir a presença de alguma doença do espectro reumatológico. Quando o acometimento pulmonar intersticial é a condição que permite o diagnóstico firmado de uma colagenose bem estabelecida, preenchendo os critérios clássicos, há pouco debate. Entretanto, ainda existe muita discussão sobre o significado, a relevância, a especificidade e o papel fisiopatológico da autoimunidade nos pacientes que tenham prioritariamente acometimento respiratório e apenas algum indício leve ou frustro de colagenose. O propósito dessa revisão foi apresentar o conhecimento atual e discutir possibilidades de interpretação da positividade de autoanticorpos em pacientes com DPI que não tenham associações etiológicas inequívocas, assim como aumentar o entendimento da história natural de uma possível nova doença e descrever possíveis implicações prognósticas. Discutimos ainda a proposição de uma nova terminologia na classificação das DPIs, a colagenose pulmão dominante.


Subject(s)
Humans , Autoantibodies/analysis , Autoimmune Diseases/diagnosis , Connective Tissue Diseases/diagnosis , Lung Diseases, Interstitial/diagnosis , Antibodies, Antinuclear/analysis , Biopsy , Diagnosis, Differential , Lung Diseases, Interstitial/classification , Lung Diseases, Interstitial/pathology , Prognosis
4.
Annals of Laboratory Medicine ; : 196-199, 2013.
Article in English | WPRIM | ID: wpr-144102

ABSTRACT

We report here a case of a 59-yr-old man with CD4+ T-cell large granular lymphocytic leukemia (T-LGL). Peripheral blood examination indicated leukocytosis (45x10(9) cells/L) that consisted of 34% neoplastic lymphoid cells. Other laboratory results indicated no specific abnormalities except for serum antinuclear antibody titer (1:640), glucose (1.39 g/L), and hemoglobin A1c (7.7%) levels. Computed tomography indicated multiple small enlarged lymph nodes (<1 cm in diameter) in both the axillary and inguinal areas, a cutaneous nodule (1.5 cm in diameter) in the left suboccipital area, and mild hepatosplenomegaly. Bone marrow examination revealed hypercellular marrow that consisted of 2.4% neoplastic lymphoid cells. The neoplastic lymphoid cells exhibited a medium size, irregularly shaped nuclei, a moderate amount of cytoplasm, and large granules in the cytoplasm. Immunohistochemical analysis indicated CD3+, CD4+, T-cell receptor betaF1+, granzyme B+, and TIA1+. Flow cytometric analysis of the neoplastic lymphoid cells revealed CD3+, cytoplasmic CD3+, CD4+, and CD7+. Cytogenetic analysis indicated an abnormal karyotype of 46,XY,inv(3)(p21q27),t(12;17)(q24.1;q21),del(13)(q14q22)[2]/46,XY[28]. The patient was diagnosed with CD4+ T-LGL and received chemotherapy (10.0 mg methotrexate). This is the second case of CD4+ T-LGL that has been reported in Korea.


Subject(s)
Humans , Male , Middle Aged , Antibodies, Antinuclear/analysis , Blood Glucose/analysis , Bone Marrow Cells/metabolism , Glycated Hemoglobin/metabolism , Immunohistochemistry , Immunophenotyping , Karyotyping , Leukemia, Large Granular Lymphocytic/diagnosis , Lymph Nodes/pathology , Neoplastic Cells, Circulating/metabolism , Tomography, X-Ray Computed
5.
Annals of Laboratory Medicine ; : 196-199, 2013.
Article in English | WPRIM | ID: wpr-144095

ABSTRACT

We report here a case of a 59-yr-old man with CD4+ T-cell large granular lymphocytic leukemia (T-LGL). Peripheral blood examination indicated leukocytosis (45x10(9) cells/L) that consisted of 34% neoplastic lymphoid cells. Other laboratory results indicated no specific abnormalities except for serum antinuclear antibody titer (1:640), glucose (1.39 g/L), and hemoglobin A1c (7.7%) levels. Computed tomography indicated multiple small enlarged lymph nodes (<1 cm in diameter) in both the axillary and inguinal areas, a cutaneous nodule (1.5 cm in diameter) in the left suboccipital area, and mild hepatosplenomegaly. Bone marrow examination revealed hypercellular marrow that consisted of 2.4% neoplastic lymphoid cells. The neoplastic lymphoid cells exhibited a medium size, irregularly shaped nuclei, a moderate amount of cytoplasm, and large granules in the cytoplasm. Immunohistochemical analysis indicated CD3+, CD4+, T-cell receptor betaF1+, granzyme B+, and TIA1+. Flow cytometric analysis of the neoplastic lymphoid cells revealed CD3+, cytoplasmic CD3+, CD4+, and CD7+. Cytogenetic analysis indicated an abnormal karyotype of 46,XY,inv(3)(p21q27),t(12;17)(q24.1;q21),del(13)(q14q22)[2]/46,XY[28]. The patient was diagnosed with CD4+ T-LGL and received chemotherapy (10.0 mg methotrexate). This is the second case of CD4+ T-LGL that has been reported in Korea.


Subject(s)
Humans , Male , Middle Aged , Antibodies, Antinuclear/analysis , Blood Glucose/analysis , Bone Marrow Cells/metabolism , Glycated Hemoglobin/metabolism , Immunohistochemistry , Immunophenotyping , Karyotyping , Leukemia, Large Granular Lymphocytic/diagnosis , Lymph Nodes/pathology , Neoplastic Cells, Circulating/metabolism , Tomography, X-Ray Computed
6.
Acta bioquím. clín. latinoam ; 46(1): 3-13, mar. 2012. ilus, tab
Article in Spanish | LILACS | ID: lil-639595

ABSTRACT

La presencia de anticuerpos antinucleares (AAN) es el denominador común de muchas enfermedades autoinmunes sistémicas y su significancia clínica depende de la metodología utilizada en su determinación. En la actualidad, la inmunofluorescencia indirecta (IFI) utilizando células HEp-2 como sustrato es la técnica más usada. Siendo un procedimiento subjetivo se deben optimizar los métodos de estandarización de las distintas variables involucradas, para asegurar la calidad de los resultados obtenidos. El uso de este sustrato permite la descripción no sólo de patrones de fluorescencia nucleares sino también citoplasmáticos y de diferentes organelas. El 29 de agosto de 2008 se llevó a cabo en Buenos Aires el Primer Consenso Argentino para la Estandarización de la Determinación de AAN por IFI-HEp-2, con la participación de 28 expertos. Se discutieron los aspectos metodológicos más importantes y se decidió llamar a la determinación "anticuerpos anti núcleo-citoplasmáticos". Se consensuó la sigla representativa de la determinación, el nombre en español de los diferentes patrones y el uso de controles de calidad internos y externos. La unificación de criterios llevará a la optimización de los resultados y a su correcta interpretación.


Antinuclear antibodies (ANA) are a common feature of many systemic autoimmune diseases. Their clinical significance depends on working conditions. Nowadays, indirect immunofluorescence (IFI), using HEp-2 cells as substrate, is the most used assay. Since IFI is a subjective method, different variables should be strictly standardized to assure the quality of the results. By using HEp-2 cells, not only a nuclear fluorescent pattern will be described but also cytoplasmic and different organelle patterns. In order to standardize the operative procedures, the 1st Argentine Consensus for AAN IFI HEp-2 determination took place in Buenos Aires on August 29, 2008, with 28 experts as participants. The most important methodological aspects were discussed and the assay was decided to be named: anti nuclear- cytoplasmic antibodies. Consesus was also CAICYThed about the acronym for the determination, the Spanish names for the different patterns and the use of internal and external quality controls. Using common criteria will improve the quality of the results and optimize assay interpretation.


A presenga de anticorpos antinucleares (AAN) é o denominador comum de muitas doengas autoimunes sistémicas e sua significancia clínica depende da metodologia utilizada em sua determinagáo. Na atualidade, a imunofluorescéncia indireta (IFI) utilizando células HEp-2 como substrato é a técnica mais utilizada. Sendo um procedimento subjetivo devem ser otimizados os métodos de padronizagáo das diferentes variáveis envolvidas, para garantir a qualidade dos resultados obtidos. O uso deste substrato permite a descrigáo náo apenas de padróes de fluorescéncia nucleares mas também citoplasmáticos e de diferentes organelas. Em 29 de agosto de 2008, foi levado a cabo, em Buenos Aires, o Primeiro Consenso Argentino para a Padronizagáo da Determinagáo de AAN por IFI-HEp-2, com a participagáo de 28 especialistas. Foram discutidos os aspectos metodológicos mais importantes e se decidiu chamar a determinagáo de "anticorpos antinúcleo-citoplasmáticos". Foi estabelecida por consenso a sigla representativa da determinagáo, o nome em espanhol dos diferentes padróes e o uso de controles de qualidade internos e externos. A unificagáo de critérios levará a otimizago dos resultados e a sua correta interpretagáo.


Subject(s)
Antibodies, Antinuclear/analysis , Antibodies, Antinuclear/immunology , Fluorescent Antibody Technique, Indirect/standards , Argentina , Quality Control , Program Evaluation , Fluorescent Antibody Technique, Indirect/methods
7.
Rev. chil. obstet. ginecol ; 77(5): 388-392, 2012. ilus
Article in Spanish | LILACS | ID: lil-657720

ABSTRACT

El lupus eritematoso sistémico (LES) es una de las patologías autoinmunes más frecuentes durante el embarazo, asociándose con distintas complicaciones fetales y neonatales, sobre todo cardíacas, secundario al traspaso de anticuerpos maternos a través de la placenta. Estos anticuerpos se unen a los cardiomioci-tos fetales, desencadenando una respuesta inflamatoria local que determina la aparición de lesiones que pueden ser permanentes y letales. Presentamos el caso de una paciente embarazada con LES, en la cual se observó en el feto la presencia de bloqueo aurículo-ventricular de primer grado y signos sugerentes de miocarditis. Estas complicaciones se caracterizan por un aumento en la morbimortalidad perinatal, por lo que las estrategias actuales están dirigidas a la detección precoz de éstas y también en la prevención de las mismas. Un tratamiento estándar aun es tema de investigación, pese a los reportes que muestran la efectividad de corticoides como la dexametasona. En embarazadas con anticuerpos anti-Ro positivo se recomienda efectuar ecocardiograma fetal seriados cada 1-2 semanas desde la semana 16, para detectar precozmente anomalías cardiacas sobre las cuales pudiese intervenirse.


Systemic lupus erythematosus (SLE) is one of the most common autoimmune disease during pregnancy, associated with various fetal and neonatal complications, especially heart disease, secondary to the transfer of maternal antibodies through the placenta. These antibodies bind to fetal cardiomyocytes, triggering a local inflammatory response that determines the appearance of lesions that may become permanent and deadly. We report a pregnant patient with SLE, in which was observed the presence of atrioventricular block of 1st degree and signs suggestive of myocarditis in the fetus. These complications are characterized by an increase in fetal and neonatal morbidity and mortality, so that current strategies are aimed at early detection of these and also in preventing them. A standard therapy for atrioventricular block is still matter of investigation, although corticosteroids like dexamethasone have been reported to be effective for associated cardiomyo-pathy. Serial echocardiograms and obstetric sonograms, performed at least every 1-2 weeks starting from the 16th week of gestational age, are recommended in anti-Ro/SSA-positive pregnant women to detect early fetal abnormalities that might be a target of preventive therapy.


Subject(s)
Humans , Female , Pregnancy , Infant, Newborn , Adult , Atrioventricular Block/immunology , Atrioventricular Block , Fetal Diseases/immunology , Fetal Diseases , Lupus Erythematosus, Systemic/immunology , Antibodies, Antinuclear/analysis , Antibodies, Antinuclear/immunology , Dexamethasone/therapeutic use , Fetal Diseases/drug therapy , Myocarditis/immunology , Myocarditis , Pregnancy Outcome , Ultrasonography, Prenatal
8.
The Korean Journal of Gastroenterology ; : 315-318, 2011.
Article in Korean | WPRIM | ID: wpr-175648

ABSTRACT

The pathogenesis of autoimmune hepatitis (AIH) is unclear, but viral infections have been proposed as a potential trigger in patients with genetic predisposition. We report a case of AIH following acute hepatitis A (AHA). A 57-year-old woman presented with fatigue and pitting edema for last 3 months. She had been diagnosed as an AHA 15 months ago based on clinical features, biochemical tests and positive HAV IgM antibody at a local clinic. Her biochemical tests was normalized one month after AHA diagnosis, but the serum levels of aminotransferase started to rise four months after AHA diagnosis. Antinuclear antibody was positive at a titer of 1:40, and anti-smooth muscle antibody was also positive. Hypergammaglobulinemia and liver pathology were typical for AIH. The patients had a score of 17 according to the International Autoimmune Hepatitis Group's system. She was given prednisolone and azathioprine and showed complete response to immunosuppressive therapy. The present case is the first report on AIH triggered by AHA in Korea.


Subject(s)
Female , Humans , Middle Aged , Acute Disease , Alanine Transaminase/blood , Antibodies, Antinuclear/analysis , Aspartate Aminotransferases/blood , Autoantibodies/analysis , Azathioprine/therapeutic use , Hepatitis A/complications , Hepatitis, Autoimmune/diagnosis , Hypergammaglobulinemia/diagnosis , Immunosuppressive Agents/therapeutic use , Liver/pathology , Prednisolone/therapeutic use
9.
The Korean Journal of Laboratory Medicine ; : 675-684, 2010.
Article in Korean | WPRIM | ID: wpr-73300

ABSTRACT

BACKGROUND: Anti-double stranded DNA antibody (anti-dsDNA) test is useful for the diagnosis and monitoring of systemic lupus erythematosus (SLE). Although several methods are available, none of them is completely satisfactory and differences among them have been reported. We evaluated the diagnostic performance of 6 commercial kits for anti-dsDNA detection. METHODS: A total of 142 sera (SLE [N=74], other systemic rheumatic diseases [N=50], other diseases [N=18]) were tested by 6 different assay kits using different antigenic sources of DNA: Crithidia luciliae immunofluorescence test (CLIFT), salmon testes (immunoblot, IB), human (ELISA I), salmon testes with nucleosome linker (ELISA II), plasmid (ELISA III), and synthetic oligonucleotides (chemiluminescence immunoassay, CLIA). RESULTS: With manufacturers' cut-off values, 6 test kits showed sensitivities of 55.4-91.9%. ELISA I had a greater sensitivity than the other five assays (P0.05). With cut-off values set at 95% of specificity, ELISA II had a higher sensitivity than ELISA III (63.5% vs. 41.9%, P<0.05). IB had poor concordance rates with other assays (42.0-65.0%). Pearson correlation coefficients among 4 quantitative assays were 0.667-0.798. CONCLUSIONS: Six different assays showed various performances depending on the methods and cut-off values used. Except IB, the other five assays can be used for the detection of anti-dsDNA.


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Antibodies, Antinuclear/analysis , Area Under Curve , Luminescent Measurements/methods , DNA/immunology , Enzyme-Linked Immunosorbent Assay/methods , Fluorescent Antibody Technique/methods , Immunoblotting/methods , Lupus Erythematosus, Systemic/diagnosis , ROC Curve , Reagent Kits, Diagnostic , Sensitivity and Specificity
10.
J. bras. patol. med. lab ; 45(3): 185-199, jun. 2009. ilus, tab
Article in Portuguese | LILACS | ID: lil-523350

ABSTRACT

OBJETIVO: O III Consenso Brasileiro para Pesquisa de Autoanticorpos em Células HEp-2 (FAN) objetivou discutir estratégias para controlar a qualidade do ensaio, promover a atualização das associações clínicas dos diversos padrões e avaliar as dificuldades de implantação do II Consenso ocorrido no ano de 2002. MÉTODOS: Nos dias 13 e 14 de abril de 2007 participaram do encontro em Goiânia pesquisadores e especialistas de diversos centros universitários e laboratórios clínicos de diferentes regiões do Brasil, com o propósito de discutir e aprovar as recomendações que visam a melhores padronização, interpretação e utilização do ensaio pelos clínicos. Foram convidados como ouvintes representantes comerciais de diferentes empresas produtoras de insumos para realização do teste de FAN. RESULTADOS E CONCLUSÃO: Dada a heterogeneidade de microscópios e reagentes disponíveis no mercado, o III Consenso enfatizou a necessidade do controle de qualidade em ensaios de imunofluorescência indireta. Foram também feitas algumas adequações na terminologia utilizada para classificar os diferentes padrões. Finalmente, foi realizada uma atualização das associações clínicas com finalidade de facilitar cada vez mais o melhor uso do ensaio pelos clínicos.


OBJECTIVE: The Third Brazilian Consensus for Autoantibodies Screening in HEp-2 Cells (ANA) had as purpose the evaluation of difficulties in the accomplishment of the 2nd Consensus recommendations that took place in the year of 2002, the discussion of strategies for quality control of the assay and the discussion of an update of the clinical associations of the several immunofluorescent patterns. METHODS: Several ANA experts from university centers and private laboratories in different areas in Brazil joined the workshop in Goiânia on 2007 April 13 and 14 with the purpose of discussing and approving the recommendations for standardization, interpretation and use of the test by physicians. Commercial representatives of different ANA slide brands were also invited as listeners to the workshop. RESULTS AND CONCLUSION: The 3rd ANA Consensus emphasized the need for quality control in indirect immunofluorescent assays since there is a considerable heterogeneity of available microscopes and reagents. It also promoted adaptations in the previously approved terminology used to classify the different patterns and finally updated the clinical associations of the several patterns with the purpose of providing guidance for interpretation of the assay by clinical pathologists and assistant physicians.


Subject(s)
Humans , Antibodies, Antinuclear/analysis , Autoantibodies/analysis , Fluorescent Antibody Technique, Indirect/methods , Autoimmune Diseases , Autoantibodies/immunology , Consensus Development Conferences as Topic , Quality Control
11.
J. bras. med ; 96(3): 51-58, jan.-mar. 2009. ilus, tab
Article in Portuguese | LILACS | ID: lil-604026

ABSTRACT

A utilização de células HEp-2 na detecção dos anticorpos antinucleares (FAN-HEp-2) constituiu-se em grande avanço metodológico. Como consequência, o teste tornou-se muito sensível, porém com diminuição da especificidade, fato comprovado pelo crescente número de exames positivos em indivíduos sabidamente hígidos. O objetivo deste artigo é fazer uma abordagem sobre os pontos importantes, para correta valorização dos achados do teste de FAN, que possa auxiliar o clínico na exata identificação de pacientes com doenças autoimunes, particularmente o lúpus eritematoso sistêmico. Os autores discutem a importância do título e do padrão na interpretação de um FAN positivo. Discutem também os possíveis significados do teste positivo em pacientes sem evidências objetivas de doenças imunológicas.


Antinuclear antibody (ANA) tests are frequently used to screen patients for chronic inflammatory diseases such as lupus erythematosus (SLE). However, the methodological advances have brought up a considerable improvement in the test's sensitivity and consequently a decrease in its specificity. This has resulted in an increasing number of positive tests in apparently healthy subjects. The present article brigs an approach on the most important points to be considered in the analyses and evaluation of an ANA test, like titer and immunofluorescence pattern of a positive test. Those points are importants parameters in the evaluation of the significance of a positive ANA-HEp-2 test that might help the identification of patients with autoimmune disease. Also, it is important to consider the possible and alternative significance of a positive ANA test in patients without objective evidence of autoimmune diseases.


Subject(s)
Humans , Male , Female , Autoimmune Diseases , Antibodies, Antinuclear/analysis , Lupus Erythematosus, Systemic/diagnosis , Sensitivity and Specificity , Fluorescent Antibody Technique, Indirect/methods , Fluorescent Antibody Technique, Indirect
13.
Arq. bras. oftalmol ; 71(3): 365-369, maio-jun. 2008. ilus, tab
Article in Portuguese | LILACS | ID: lil-486112

ABSTRACT

OBJETIVO: Estimar a prevalência de manifestações oculares na população local de artrite reumatóide (AR). Estimar se a presença de auto-anticorpos como fator reumatóide (FR) e fator antinuclear (FAN) influi no aparecimento destas manifestações e se existe associação entre o aparecimento de manifestações oculares e índice funcional do paciente, idade ao diagnóstico e tempo de doença. MÉTODOS: Foram estudados retrospectivamente 198 prontuários de pacientes com AR, acompanhados durante o período de 2003 a 2006. Avaliou-se a prevalência das manifestações oftalmológicas, perfil de auto-anticorpos, dados demográficos e índice funcional de Steinbrock destes pacientes. RESULTADOS: Síndrome de Sjõgren secundária apareceu em 12,1 por cento dos pacientes sendo mais comum em mulheres (p=0,049) e em pacientes com maior dano articular (p=0,016). Ceratite ulcerativa e esclerite incidiram em torno de 2 por cento dos pacientes. Fator reumatóide (FR) e fator antinuclear (FAN) assim como tempo de doença e idade do paciente ao diagnóstico não influíram no aparecimento das manifestações estudadas. CONCLUSÃO: A síndrome de Sjõgren secundária é a manifestação ocular mais prevalente em pacientes com AR, sendo mais comum em mulheres e em pacientes com mais disfunção articular.


PURPOSE: To study the prevalence of eye manifestations in the local rheumatoid arthritis (RA) population, as well as to know if the presence of rheumatoid factor (RF) and antinuclear antibodies (ANA) affect this profile. To study if there is association between eye manifestations and patient's articular functional index, age at diagnosis and illness duration. METHODS: We reviewed 198 charts of rheumatoid arthritis patients followed-up from 2003 to 2006. They were studied for: prevalence of ophthalmologic manifestations, autoantibody profile, demographic data and Steinbrock's functional index. RESULTS: Secondary Sjõgren's syndrome was seen in 12.1 percent of the patients being more common in women (p=0.049) and in patients with greater articular damage (p=0.016). Ulcerative keratitis and scleritis appeared in 2 percent of patients each. Antinuclear antibodies (ANA) and rheumatoid factor (RF) as well as illness duration and age at diagnosis had no influence in the appearance of eye manifestations. CONCLUSION: Secondary Sjõgren syndrome was the most common ocular manifestation in patients with RA, mainly in women and patients with greater joint damage.


Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Young Adult , Arthritis, Rheumatoid/complications , Scleritis/etiology , Sjogren's Syndrome/etiology , Age Distribution , Antibodies, Antinuclear/analysis , Arthritis, Rheumatoid/epidemiology , Arthritis, Rheumatoid/immunology , Brazil/epidemiology , Epidemiologic Methods , Rheumatoid Factor/analysis , Scleritis/diagnosis , Scleritis/epidemiology , Sjogren's Syndrome/diagnosis , Sjogren's Syndrome/epidemiology , Time Factors , Young Adult
14.
The Korean Journal of Gastroenterology ; : 190-193, 2008.
Article in Korean | WPRIM | ID: wpr-210430

ABSTRACT

Overlap of autoimmune hepatitis and systemic lupus erythematosus (SLE) is a comparatively rare condition. Although both autoimmune hepatitis and SLE can share common autoimmune features such as polyarthralgia, hypergammaglobulinemia and positive ANA, it has been considered as two different entities. We report a case of anti-LKM1 positive autoimmune hepatitis who developed SLE two years later. The presence of interface hepatitis with lymphoplasma cell infiltrates and rosette formation points to the autoimmune hepatitis rather than SLE hepatitis. Autoimmune hepatitis is infrequently accompanied by SLE, therefore, it could be recommended to investigate for SLE in patients with autoimmune hepatitis.


Subject(s)
Female , Humans , Young Adult , Antibodies, Antinuclear/analysis , Autoantibodies/analysis , Echocardiography , Hepatitis, Autoimmune/complications , Liver/pathology , Lupus Erythematosus, Systemic/complications
15.
The Korean Journal of Laboratory Medicine ; : 353-361, 2008.
Article in Korean | WPRIM | ID: wpr-39345

ABSTRACT

BACKGROUND: Detection of antibodies to extractable nuclear antigens (ENAs) and dsDNA is needed for the diagnosis of and predicting prognosis in systemic autoimmune diseases. Recently introduced line immunoassay (LIA) has the advantage of detecting several autoantibodies simultaneously, and we evaluated its usefulness in the diagnosis of autoimmune diseases in comparison with enzyme-linked immunosorbent assay (ELISA). METHODS: Samples were collected from 437 patients referred by rheumatologists. FANA (fluorescent antinuclear antibody) test and LIA for the detection of 13 different autoantibodies, including 6 ENAs and dsDNA were performed. LIA-positive samples for ENA or dsDNA antibodies were further tested with ELISA. Final diagnosis was made by rheumatologists according to the diagnostic criteria. Agreement of results between LIA and ELISA was analyzed in 53 selected patients with systemic autoimmune diseases. RESULTS: The LIA detected antibodies to ENA and dsDNA in 118 and 22 patients, respectively, and ELISA detected 70.3% (83/118) and 45.5% (10/22) of LIA positive samples. Especially, 60.2% (71/118) of patients with positive ENA antibody on LIA was diagnosed as systemic autoimmune diseases. Patients having strong FANA titer and homogenous/speckled pattern showed higher prevalence of autoantibodies, but a small proportion of FANA negative patients also showed positive reactivity (LIA 10.8%, ELISA 5.2%). LIA showed a good agreement with ELISA for the anti-ENA antibodies (> or =80%), and a lower agreement for the anti-dsDNA antibody (67.9%). CONCLUSIONS: LIA detecting several autoantibodies simultaneously might replace ELISA for anti-ENA antibodies, but not for anti-dsDNA antibodies. When LIA is performed considering clinical manifestations and FANA, it could contribute to the diagnosis of systemic autoimmune disease.


Subject(s)
Female , Humans , Male , Middle Aged , Antibodies, Antinuclear/analysis , Antigens, Nuclear/immunology , Autoimmune Diseases/diagnosis , DNA/immunology , Enzyme-Linked Immunosorbent Assay , Fluorescent Antibody Technique, Indirect , Immunoassay , Reagent Kits, Diagnostic , Reproducibility of Results
16.
Arq. bras. oftalmol ; 70(6): 953-960, nov.-dez. 2007. ilus, graf, tab
Article in Portuguese | LILACS | ID: lil-474101

ABSTRACT

OBJETIVO: Avaliar a cinética celular do epitélio corneano de coelhas em três situações: controle, hiperproliferação e hipoproliferação celular, com a utilização dos marcadores de proliferação celular BrdU, Ki-67/MIB-1 e AgNOR. MÉTODOS: Foram utilizadas quinze coelhas albinas que tiveram seus olhos aleatoriamente divididos em 3 grupos (A, B e C). O grupo A incluiu olhos que foram submetidos à instilação de tampão fosfato (total de 10 olhos); o grupo B, instilação de tampão fosfato após a remoção de uma área central do epitélio corneano de 10 mm (total de 10 olhos) e o grupo C, instilação de 5-fluoruracil em superfície ocular íntegra (total de 10 olhos). RESULTADOS: Os resultados da média e desvio-padrão do número de células marcadas pela BrdU nos grupos A, B e C foram, respectivamente, de 7,17 ± 0,74; 35,00 ± 3,01 e 0,22 ± 0,1 células marcadas por 100 células basais. As diferenças entre os grupos foram estatisticamente significantes. A média e o desvio padrão do número de células marcadas utilizando o Ki-67 foram de 7,55 ± 1,22 no grupo A; 35,55 ± 3,84 no grupo B e 0,34 ± 0,14 no grupo C. As diferenças entre os grupos foram estatisticamente significantes. A média e o desvio-padrão da medida da área das NORs no grupo A foram de 1,92 ± 0,24, no grupo B foram de 3,61 ± 0,27 e no grupo C foram de 1,71 ± 0,26. CONCLUSÕES: Os marcadores BrdU, Ki-67 e AgNOR apresentaram uma correlação positiva e estatisticamente significante nas situações de proliferação celular avaliadas (controle, hiperproliferação e hipoproliferação); o emprego do AgNOR não permitiu identificar diferenças na proliferação celular nas situações controle e hipoproliferação e houve maior concordância de resultados entre a BrdU e o Ki-67 nas três situações de proliferação celular.


PURPOSE: In order to maintain its clear and uniform structure, the corneal epithelium needs constant equilibrium between production (division) and desquamation of its epithelial cells. The author aimed to evaluate the cell kinetics of corneal epithelium of rabbits in three situations (control, hypoproliferation and hyperproliferation) using BrdU, Ki-67/MIB-1 and AgNORs proliferation markers. METHODS: Fifteen white female rabbits had their eyes randomly divided into three groups (A, B and. C). Group A included eyes submitted to phosphate buffer saline instillation (total 10 eyes); group B, instillation of phosphate buffer saline after removing a 10 mm central area of the corneal epithelium (total 10 eyes) and group C, instillation of 5-fluorouracil in normal epithelium (total 10 eyes). RESULTS: The results of the mean number and standard deviation of the marked cells using BrdU in groups A, B e C were, respectively, 7.17 ± 0.74; 35.00 ± 3.01 e 0.22 ± 0.1 marked cells per 100 basal cells. Differences among groups were statistically significant. The mean number and standard deviation of the labelled cells using Ki-67 were 7.55 ± 1.22 in group A; 35.55 ± 3.84 in group B and 0.34 ± 0.14 in group C. Differences among groups were statistically significant. The mean area and standard deviation of NORs in group A were 1.92 ± 0.24, in group B, 3.61 ± 0.27 and in group C, 1.71 ± 0.26. CONCLUSIONS: The markers BrdU, Ki-67 and AgNOR showed a positive correlation with statistical significance among the cellular proliferation situations studied (control, hypoproliferation and hyperproliferation); the AgNOR did not show statistically significant differences among the control and hypoproliferation situations and there was more agreement in the results among markers BrdU and Ki-67 in three cell proliferation situations.


Subject(s)
Animals , Female , Rabbits , Cell Division/physiology , Cornea/cytology , Epithelial Cells/metabolism , Antibodies, Antinuclear/analysis , Antibodies, Monoclonal/analysis , Biomarkers/analysis , Bromodeoxyuridine/analysis , Cell Division/drug effects , Cell Proliferation/drug effects , Cornea/drug effects , Cornea/injuries , Cornea/metabolism , Epithelial Cells/drug effects , Fluorouracil/administration & dosage , Kinetics , /analysis , Nucleolus Organizer Region/chemistry , Phosphates/administration & dosage , Random Allocation , Silver Staining , Statistics, Nonparametric , Sodium Chloride/administration & dosage
17.
Rev. Assoc. Med. Bras. (1992, Impr.) ; 53(5): 439-445, set.-out. 2007. tab
Article in Portuguese | LILACS | ID: lil-465258

ABSTRACT

A pesquisa de anticorpos contra antígenos celulares (FAN-HEp-2), historicamente conhecida como FAN (fator antinúcleo), tem passado por modificações metodológicas que exigem reflexão sobre suas características de sensibilidade e especificidade, para que haja uma adequada valorização dos resultados obtidos. Atualmente, o exame é marcado por elevada sensibilidade e questionável especificidade, resultando em elevado número de exames positivos em indivíduos não auto-imunes. O reconhecimento de que uma fração substancial da população apresenta o teste de FAN-HEp-2 reagente ocasiona a necessidade de busca de características que possam distinguir os testes positivos em pacientes com doença auto-imune daqueles observados em indivíduos não auto-imunes. Entre essas características, encontram-se o título da reação e o padrão de fluorescência observado. Em particular, deve-se ter em mente que o padrão de fluorescência é resultante do reconhecimento de diferentes estruturas celulares pelos anticorpos e, portanto, o padrão de fluorescência fornece uma indicação preliminar dos possíveis antígenos que estão sendo reconhecidos. Um exemplo emblemático é representado pelo padrão nuclear pontilhado fino denso (PFd). Inicialmente pesquisado por Ochs et al. (1984), em grupo clínico restrito de pacientes com cistite intersticial, estudos ulteriores demonstraram sua alta freqüência na prática laboratorial em indivíduos com diversas condições não auto-imunes. De fato, este padrão é um dos mais freqüentes entre indivíduos não auto-imunes com reação FAN-HEp-2 positiva. A presente revisão tem como objetivo fornecer elementos que permitam ao clínico exercitar uma interpretação crítica dos resultados de FAN-HEp-2, incluindo a análise do título e do padrão de fluorescência.


Determination of autoantibodies against cellular antigens (ANA-HEp-2) has undergone several methodological changes over the decades and for an appropriate evaluation of results requires reflection on its sensitivity and specificity properties. Currently the test is known to have high sensitivity and questionable specificity since it is frequently positive in a considerable number of non-autoimmune subjects. Awareness that a substantial portion of the population has a positive ANA-HEp-2 test demands that characteristics permitting to distinguish positive tests in autoimmune patients from positive tests in non-autoimmune subjects be identified. Among these characteristics are noteworthy the titer and the fluorescence pattern. In particular, one must bear in mind that the fluorescence pattern results from recognition by autoantibodies of distinct cellular structures and, therefore, the fluorescence pattern provides a preliminary indication of possible autoantigens targeted by the sera being tested. An emblematic example is the nuclear dense fine speckled pattern. It was originally studied by Ochs and collaborators in 1994 in a restricted number of patients with interstitial cystitis. Further studies demonstrated its frequent occurrence in laboratory practice in individuals with diverse non-autoimmune clinical conditions. Indeed, this pattern is one of the most frequently observed in non-autoimmune patients with an ANA-HEp-2 positive reaction. The present review intends to provide elements allowing the clinician to perform a critical interpretation of results of an ANA-HE-2 test, including analysis of the titer and the fluorescence pattern.


Subject(s)
Humans , Antibodies, Antinuclear/analysis , Autoantibodies/immunology , Autoimmune Diseases/diagnosis , Fluorescent Antibody Technique, Indirect , Autoimmune Diseases/immunology , Sensitivity and Specificity
18.
Article in English | IMSEAR | ID: sea-38998

ABSTRACT

BACKGROUND: Anti-Ro antibody may directly react against either Ro60 or Ro52 or both antigens. To be more applicable for routine laboratory practice, the specific antigen type for antibody detection should be identified before test application. OBJECTIVE: Investigate the prevalence of 60 kDa and 52 kDa Ro/SS-A antibodies in Thai patients' sera in Siriraj Hospital. MATERIAL AND METHOD: Specimens for anti-Ro were requested between June and December 2005. They were tested with EUROLINE test kit for prevalence determination. The principle of the test is a qualitative in-vitro-assay that contains test strips coated with parallel lines of 14 highly purified antigens. Of 84 specimens requested for anti-Ro antibody, 76 were collected and tested with the EUROLINE test kits and eight were excluded due to inadequacy. RESULTS: The prevalence of anti-Ro60 and anti-Ro52 of all sera tested for anti-Ro by EUROLINE test kit were 30% (95% CI: 20-40%) and 26% (95% CI: 16-36%), respectively; and, those in anti-Ro positive Thai sera were 82% (95% CI: 68-96%) and 71% (95% CI: 54-88%), respectively. The prevalence of anti-Ro52 alone in anti-Ro positive Thai sera and all specimens requested for anti-Ro was about 18% (95% CI: 4-32%) and 7% (95% CI: 1-13%), respectively. The agreement and Kappa value between the two methods were 0.9 and 0.77, respectively. The study suggests that the test for anti-Ro detection should provide both Ro 60 and Ro 52 antigens. CONCLUSION: The prevalence of both anti-Ro 60 and anti-Ro 52 were quite common, therefore, the test for this specific antibody should provide both antigens for antibody detection.


Subject(s)
Antibodies, Antinuclear/analysis , Autoantibodies , Biomarkers/analysis , Enzyme-Linked Immunosorbent Assay/methods , Hospitals, University , Humans , Prevalence , RNA, Small Cytoplasmic , Reagent Kits, Diagnostic , Sensitivity and Specificity , Thailand/epidemiology
19.
West Indian med. j ; 56(2): 130-133, Mar. 2007. tab
Article in English | LILACS | ID: lil-476418

ABSTRACT

OBJECTIVE: The relationship between human leukocyte antigens class II (HLA) and antinuclear antibodies was investigated in Jamaican patients with Systemic Lupus Erythematosus (SLE). METHODS: Samples of blood of 82 patients with SLE and 75 healthy controls were tested for antinuclear antibodies using the fluorescent antinuclear antibody (FANA) test, counterimmunoelectrophoresis (CIEP) and the Crithidia luciliae immunofluorescence test (CL-IFT). A DNA-based HLA typing method was used to determine the frequencies of alleles of HLA-DRB1, DRB3, DRB4 and DRB5 in patients and healthy controls. RESULTS: The FANA test was positive in all of the sera from patients with SLE. Anti-dsDNA antibodies were present in 49% (40/82), anti-Sm/RNP 44% (36/82) and anti-Ro/La 43% (35/82) of the sera from SLE patients. The frequency of HLA-DR4 was significantly lower in SLE patients than in healthy controls (2/82, 2% vs 15/75, 20%; RR = 0.12; p = 0.0004; CP = 0.005) but no other HLA-DRB1 SLE associations were found. A positive HLA-DR3 anti-Ro/La antibody association was found in the patients with SLE (9/21, 43% vs 5/55, 9%; odds ratio (OR) = 7.5; CP = 0.01). In contrast, possession of HLA-DR6 was negatively associated with the absence of anti-dsDNA antibodies (9/32, 28% vs 27/44, 61%; OR = 0.2; CP = 0.05). CONCLUSION: The HLA-DR6 allele is associated with the absence of antinuclear antibodies and HLA-DR3 with the presence of anti-Ro/La antibodies in Jamaican patients with SLE. However, these results and those of previous studies of Jamaican patients suggest that the HLA-DR3 association with the development of SLE reported in other populations might in fact reflect the association of HLA-DR3 with anti-Ro/La antibodies. Further investigations are needed to determine whether HLA-DRB antinuclear antibody associations define clinical subsets of SLE in Jamaican patients.


OBJETIVO Se investigó la relación entre los antígenos de leucocito humano (human leukocyte antigens o HLAs). Clase II y los anticuerpos antinucleares en pacientes jamaicanos con lupus eritematoso sistémico (LES). MÉTODOS: Se examinaron muestras de sangre de 82 pacientes con LES y 75 controles saludables para determinar la presencia de anticuerpos antinucleares, usando la prueba del anticuerpo antinuclear fluorescente (FANA), la contrainmunoelectroforesis (CIEP) y el test de inmunofluorescencia con Crithidia luciliae (CL-IFT). Un método de tipificación HLA basado en el ADN fue usado para determinar las frecuencias de aleles de HLA-DRB1, DRB3, DRB4 y DRB5 tanto en los pacientes como en los controles saludables. RESULTADOS: La prueba FANA fue positiva en todos los sueros de pacientes con LES. Anticuerpos anti-dsADN se hallaban presentes en 49% (40/82), anti-Sm/RNP en 44% (36/82) y anti-Ro/La en 43% (35/82) de los sueros de los pacientes de LES. La frecuencia de HLA-DR4 fue significativamente más baja en los pacientes con LES que en los controles saludables (2/82, 2% vs 15/75, 20%; RR = 0.12; p = 0.0004; CP = 0.005) pero no se hallaron otras asociaciones de LES con HLA-DRB1. Se halló una asociación positiva de anticuerpos HLA-DR3 anti-Ro/La en los pacientes con LES (9/21, 43% vs 5/55, 9%; odds ratio (OR) = 7.5; CP = 0.01). En contraste con ello, la posesión de HLA-DR6m estuvo asociada negativamente con la ausencia de anticuerpos anti-dsADN (9/32, 28% vs 27/44, 61%; OR = 0.2; CP = 0.05). CONCLUSIÓN: El alele HLA-DR6 está asociado con la ausencia de anticuerpos antinucleares y el de HLA-DR3 con la presencia de anticuerpos anti-Ro/La en pacientes jamaicanos con LES. Sin embargo, estos resultados al igual que los de los previos estudios de pacientes jamaicanos, sugieren que la asociación HLA-DR3 con el desarrollo de LES reportado en otras poblaciones podría de hecho reflejar la asociación de HLA-DR3 con anticuerpos anti-Ro/La. Se requieren investigaciones ulteriores a fin de determinar si las asociaciones de anticuerpo antinuclear HLA-DRB definen subconjuntos de LES en pacientes jamaicanos.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Aged , Antibodies, Antinuclear/analysis , HLA-DR Antigens/genetics , Genes, MHC Class II/genetics , Lupus Erythematosus, Systemic/genetics , Counterimmunoelectrophoresis , Case-Control Studies , Risk Factors , Jamaica/epidemiology , Lupus Erythematosus, Systemic/epidemiology , Prevalence
20.
Arq. neuropsiquiatr ; 63(3B): 864-869, set. 2005. ilus
Article in English | LILACS | ID: lil-445129

ABSTRACT

Pituitary carcinomas are rare neoplasms characterized by craniospinal and/or systemic metastases originated from the pituitary. Their histopathology is frequently indistinguishable from that of benign adenomas. The development of markers that better reflect their behavior is desirable. We present the case of a 47 year-old man with a prolactin-secreting macroadenoma who was submitted to surgeries, cranial radiation therapy, and bromocriptine treatment, but evolved to a fatal outcome after the disclosure of intracranial metastases. Tumor samples underwent p53 and Ki-67 immunohistochemical assessment. p53 was absent in all samples, a rare finding among pituitary carcinomas. Ki-67 proliferative index was 2.80% in the original tumor, 4.40% in the relapse, and 4.45% in the metastasis. The figure in the relapse is higher than the expected for a noninvasive adenoma. In conclusion, p53 staining is not positive in all pituitary carcinomas. A high Ki-67 proliferative index in a pituitary adenoma might indicate a more aggressive behavior.


Carcinomas pituitários são neoplasias raras caracterizadas pela presença de metástases cranio-espinhais e/ou sistêmicas originadas da hipófise. Sua histopatologia é freqüentemente indistinguível daquela dos adenomas benignos. O desenvolvimento de marcadores que melhor reflitam o seu comportamento é desejável. Apresentamos o caso de um homem de 47 anos com um macroadenoma secretor de prolactina que foi submetido a procedimentos cirúrgicos, radioterapia e tratamento com bromocriptina, mas que evoluiu para o óbito após o descobrimento de metástases intracranianas. Amostras do tumor foram submetidas à análise imuno-histoquímica para os antígenos p53 e Ki-67. A coloração para p53 foi negativa em todas as amostras, um achado raro entre os carcinomas pituitários. O índice proliferativo Ki-67 foi 2,80% no tumor original, 4,40% na recidiva e 4,45% na metástase. O valor obtido na recidiva é maior que o esperado para um adenoma não-invasor. Concluindo, a coloração para p53 não é positiva em todos os carcinomas pituitários. Um índice proliferativo Ki-67 alto em um adenoma pituitário poderia indicar um comportamento mais agressivo.


Subject(s)
Humans , Male , Middle Aged , /analysis , Biomarkers, Tumor/analysis , Pituitary Neoplasms/pathology , Meningeal Neoplasms/secondary , Prolactinoma/secondary , Antibodies, Antinuclear/analysis , Antibodies, Monoclonal/analysis , Biopsy , Fatal Outcome , Immunohistochemistry , Magnetic Resonance Imaging , Neoplasm Invasiveness , Pituitary Neoplasms , Meningeal Neoplasms , Prolactin/blood , Prolactinoma , Sella Turcica/pathology , Sella Turcica
SELECTION OF CITATIONS
SEARCH DETAIL